



Advances in Phytopharmaceutical Standardization and Quality Control: Analytical Strategies, Regulatory Frameworks, and Translational Challenges

Wei Liang Zhang ^{1*}, Xiao Min Chen ², Hao Jun Liu ³, Li Na Zhao ⁴

¹ State Key Laboratory of Pharmaceutical Biotechnology, Peking University, China

² School of Pharmacy, Fudan University, China

³ Institute of Drug Delivery Systems, Shanghai Jiao Tong University, China

⁴ Department of Nanomedicine, Zhejiang University, China

* Corresponding Author: **Wei Liang Zhang**

Article Info

ISSN (online): 3107-393X

Volume: 01

Issue: 01

January – February 2024

Received: 13-11-2023

Accepted: 15-12-2023

Published: 17-01-2024

Page No: 40-47

Abstract

Phytopharmaceuticals represent a scientifically validated class of plant-derived therapeutic products requiring rigorous standardization and quality control to ensure clinical efficacy, safety, and regulatory compliance. The inherent chemical complexity and variability of botanical materials pose substantial challenges to reproducibility, necessitating advanced analytical strategies and robust quality assurance frameworks. This review critically examines the contemporary approaches to phytopharmaceutical standardization, emphasizing marker-based characterization, chemical fingerprinting, and multi-platform analytical methodologies including chromatographic, spectroscopic, and hyphenated techniques. The integration of chemometric analysis, omics technologies, and artificial intelligence-driven quality prediction systems is transforming traditional quality control paradigms. Regulatory frameworks established by the World Health Organization, European Medicines Agency, and United States Food and Drug Administration provide essential guidelines for good manufacturing practice implementation, yet significant gaps persist in harmonization and standard reference material availability. The translational relevance of stringent quality control extends beyond regulatory compliance to encompass therapeutic consistency, pharmacovigilance, and evidence-based clinical acceptance. Current challenges include biological variability management, analytical method validation across diverse matrices, scalability of advanced techniques to industrial settings, and the establishment of universal quality benchmarks. Future perspectives highlight the potential of portable analytical devices, real-time quality monitoring, blockchain-enabled traceability, and integrated quality-by-design approaches. This review provides pharmaceutical scientists, regulatory specialists, and quality control professionals with a comprehensive understanding of the analytical, regulatory, and translational dimensions of phytopharmaceutical quality assurance.

DOI:

Keywords: phytopharmaceutical standardization, quality control, chemical fingerprinting, regulatory compliance, analytical techniques, marker compounds

1. Introduction

Phytopharmaceuticals occupy a unique position within the pharmaceutical landscape, bridging traditional botanical medicine with modern scientific validation and regulatory oversight ^[1, 2]. Unlike conventional synthetic drugs characterized by single molecular entities, phytopharmaceuticals comprise complex mixtures of bioactive constituents whose therapeutic effects often result from synergistic interactions among multiple chemical components ^[3, 4]. This inherent complexity, while potentially

advantageous for multi-target therapeutic action, presents formidable challenges for standardization, quality control, and regulatory assessment [5, 6].

The global phytopharmaceutical market has experienced substantial growth, driven by increasing consumer preference for natural products, growing evidence supporting efficacy and safety, and expanding regulatory recognition [7, 8]. However, this expansion has simultaneously amplified concerns regarding product quality, consistency, and adulteration, with significant implications for patient safety and therapeutic outcomes [9, 10]. The intrinsic variability of botanical materials arising from genetic diversity, environmental factors, cultivation practices, harvesting conditions, and post-harvest processing necessitates comprehensive quality control strategies throughout the production chain [11, 12].

Contemporary phytopharmaceutical quality assurance has evolved from simple organoleptic evaluation and basic chemical testing toward sophisticated multi-dimensional analytical approaches integrating advanced instrumentation, computational methods, and systems biology perspectives [13, 14]. The paradigm shift from single-marker quantification to comprehensive chemical profiling reflects recognition that therapeutic activity and product quality cannot be adequately characterized by individual compounds alone [15, 16]. Regulatory agencies worldwide have responded by developing specific guidelines for phytopharmaceutical evaluation, although significant variations persist in requirements and approval pathways [17, 18].

This review critically examines the current state of phytopharmaceutical standardization and quality control, focusing on analytical methodologies, regulatory frameworks, and translational challenges. The objective is to provide pharmaceutical scientists and regulatory professionals with an integrated understanding of contemporary quality assurance strategies and identify key areas requiring innovation and harmonization.

2. Concept and Rationale for Phytopharmaceutical Standardization

Phytopharmaceutical standardization encompasses the systematic characterization and quantification of botanical materials and derived products to ensure consistent chemical composition, therapeutic efficacy, and safety profiles [19, 20]. The fundamental rationale for standardization stems from the recognition that biological variability inherent to plant materials directly impacts product quality and clinical outcomes [21]. Unlike synthetic pharmaceuticals manufactured under controlled conditions with predictable chemical structures, phytopharmaceuticals originate from living organisms subject to genetic variation and environmental influences [22, 23].

The standardization process aims to minimize batch-to-batch variation by establishing defined acceptance criteria for identity, purity, content, and quality [24]. This involves multiple hierarchical levels: botanical identity verification, chemical profiling, biological activity assessment, and pharmaceutical quality evaluation [25, 26]. The concept extends beyond simple marker compound quantification to encompass holistic chemical fingerprinting that captures the complexity of phytochemical compositions [27, 28].

Marker-based standardization represents the most widely implemented approach, utilizing specific compounds as quantitative or qualitative benchmarks [29]. Active markers

possess demonstrated pharmacological activity and direct therapeutic relevance, while analytical markers facilitate quality control despite uncertain pharmacological contributions [30]. Chemical markers ideally exhibit stability, ease of detection, and presence in sufficient quantities for reliable quantification [31]. However, the selection of appropriate markers remains contentious, as single compounds rarely capture the full therapeutic potential of complex botanical extracts [32].

Chemical fingerprinting has emerged as a complementary strategy providing comprehensive chromatographic or spectroscopic profiles that serve as unique product signatures [33, 34]. This approach acknowledges that therapeutic effects result from multiple constituents acting synergistically, requiring holistic quality assessment rather than reductionist single-marker focus [35]. Fingerprint analysis enables detection of adulteration, authentication of botanical sources, and monitoring of manufacturing consistency [36, 37].

The rationale for rigorous standardization extends to regulatory compliance, market authorization, pharmacovigilance, and evidence-based clinical integration [38]. Without reproducible chemical composition, clinical trial results become difficult to interpret and replicate, hindering evidence generation and regulatory acceptance [39, 40].

3. Analytical Techniques for Quality Control

Contemporary phytopharmaceutical quality control employs diverse analytical platforms, each offering distinct advantages for characterizing chemical complexity and ensuring product consistency (Table 1). Chromatographic techniques constitute the cornerstone of phytochemical analysis, providing separation capabilities essential for complex mixture characterization [41, 42].

High-performance liquid chromatography (HPLC) coupled with various detection systems represents the most prevalent methodology for phytopharmaceutical standardization [43]. Reverse-phase HPLC with ultraviolet-visible (UV-Vis) or photodiode array (PDA) detection enables simultaneous quantification of multiple marker compounds and generation of characteristic fingerprint profiles [44, 45]. Ultra-high-performance liquid chromatography (UHPLC) offers enhanced resolution, sensitivity, and analysis speed, facilitating comprehensive chemical profiling [46]. Thin-layer chromatography (TLC), despite technological advances, remains valuable for preliminary screening and identity confirmation due to simplicity and cost-effectiveness [47].

Gas chromatography (GC) provides superior resolution for volatile and semi-volatile constituents, particularly essential oils and terpenoid compounds [48]. GC-mass spectrometry (GC-MS) hyphenation enables compound identification through spectral library matching and structural elucidation [49, 50]. However, applicability limitations exist for thermally labile and non-volatile phytochemicals requiring derivatization or alternative techniques [51].

Hyphenated techniques combining chromatographic separation with mass spectrometry detection have revolutionized phytochemical analysis by providing simultaneous separation, detection, identification, and quantification capabilities [52, 53]. Liquid chromatography-mass spectrometry (LC-MS) and its high-resolution variants (LC-HRMS) enable comprehensive metabolomic profiling, unknown compound identification, and trace-level contaminant detection [54, 55]. Tandem mass spectrometry

(MS/MS) offers enhanced specificity through fragment ion monitoring and structural confirmation ^[56].

Spectroscopic techniques provide rapid, non-destructive alternatives for quality assessment ^[57]. Nuclear magnetic resonance (NMR) spectroscopy delivers detailed structural information and absolute quantification without reference standards, enabling comprehensive fingerprinting and authentication. Fourier-transform infrared (FTIR) spectroscopy facilitates rapid screening, identity verification, and detection of chemical modifications. Near-infrared (NIR) spectroscopy offers potential for at-line and online quality monitoring in manufacturing environments.

Emerging technologies include capillary electrophoresis providing high-resolution separation with minimal sample requirements, and DNA-based molecular techniques for unambiguous botanical authentication. Chemometric approaches including principal component analysis (PCA), partial least squares (PLS), and artificial neural networks transform complex analytical data into interpretable quality metrics and predictive models.

4. Regulatory and Industrial Considerations

Regulatory frameworks governing phytopharmaceutical quality vary substantially across jurisdictions, reflecting divergent philosophical approaches and historical contexts. The World Health Organization (WHO) has established comprehensive guidelines for quality control of herbal medicines, emphasizing good agricultural and collection practices (GACP), good manufacturing practices (GMP), and standardized analytical methodologies. These guidelines serve as reference standards particularly for developing countries establishing phytopharmaceutical regulatory systems.

The European Medicines Agency (EMA) operates a dual regulatory pathway for herbal products: traditional use registration based on established safety and plausibility, and well-established use registration requiring demonstration of efficacy through clinical evidence. The EMA's Committee on Herbal Medicinal Products (HMPC) develops monographs specifying quality standards, therapeutic indications, and safety information for individual botanical species. European Pharmacopoeia monographs establish mandatory quality specifications including identity tests, assays, and purity requirements.

The United States Food and Drug Administration (FDA) regulates botanical products under multiple frameworks depending on intended use and claims. Prescription botanical drugs undergo rigorous evaluation similar to conventional pharmaceuticals through the Investigational New Drug (IND) and New Drug Application (NDA) processes. The FDA's Botanical Drug Development Guidance emphasizes the importance of comprehensive chemical characterization, manufacturing controls, and quality consistency throughout clinical development.

Good Manufacturing Practice implementation represents a critical regulatory requirement ensuring consistent production quality. GMP encompasses facility design, equipment qualification, process validation, personnel training, documentation systems, and quality management. Phytopharmaceutical GMP faces unique challenges including raw material variability, extraction process optimization, and analytical method validation for complex matrices.

Standard reference materials (SRMs) availability remains limited for many botanical species, complicating method validation and quality assurance. Collaborative efforts by organizations including the National Institute of Standards and Technology (NIST) and European Directorate for the Quality of Medicines & HealthCare (EDQM) aim to expand SRM availability.

Industrial implementation of advanced analytical techniques encounters practical barriers including cost, technical expertise requirements, and throughput limitations. Risk-based quality control strategies prioritizing critical quality attributes offer pragmatic approaches for resource allocation. Quality-by-design (QbD) principles applied to phytopharmaceutical development enable systematic identification of critical process parameters and establishment of design spaces ensuring consistent quality.

5. Clinical and Translational Relevance

The clinical relevance of rigorous phytopharmaceutical quality control extends beyond regulatory compliance to fundamentally impact therapeutic outcomes, safety profiles, and evidence-based integration into healthcare systems. Inconsistent product quality represents a significant barrier to clinical acceptance and reproducible therapeutic effects, undermining the credibility of phytopharmaceutical interventions.

Pharmacokinetic and pharmacodynamic variability resulting from inconsistent chemical composition directly influences therapeutic efficacy and dose-response relationships. Well-characterized, standardized products enable establishment of evidence-based dosing regimens and rational therapeutic protocols. Clinical trials employing rigorously standardized phytopharmaceuticals generate reliable efficacy and safety data applicable to broader clinical practice.

Safety considerations encompass not only the inherent toxicity of botanical constituents but also risks associated with contamination, adulteration, and misidentification. Heavy metal contamination, pesticide residues, microbial contamination, and intentional adulteration with synthetic drugs represent serious safety concerns addressable through comprehensive quality control. Standardization facilitates pharmacovigilance by enabling accurate product identification and adverse event attribution.

Drug interaction assessment requires well-defined chemical compositions to predict potential pharmacokinetic and pharmacodynamic interactions with conventional medications. The increasing prevalence of concomitant use of phytopharmaceuticals with prescription drugs necessitates reliable product characterization for clinical risk assessment. Translational research bridging preclinical investigations and clinical applications depends critically on product consistency. Animal studies and mechanistic investigations using poorly characterized botanical products yield results of limited clinical applicability. Conversely, well-standardized products enable meaningful translation of mechanistic insights into clinical hypotheses and therapeutic applications. Healthcare provider acceptance and integration of phytopharmaceuticals into evidence-based practice require confidence in product quality and therapeutic reliability. Professional organizations and clinical guidelines increasingly emphasize the importance of product standardization in therapeutic recommendations.

6. Challenges and Future Perspectives

Despite substantial progress in analytical capabilities and regulatory frameworks, significant challenges persist in phytopharmaceutical standardization and quality control (Table 3). Biological variability inherent to botanical materials remains the fundamental obstacle to achieving pharmaceutical-grade consistency. Environmental factors including climate, soil composition, altitude, and seasonal variations substantially influence phytochemical profiles. Genetic diversity among wild-harvested populations and even cultivated materials contributes additional variability.

Analytical method validation for complex botanical matrices presents technical challenges distinct from single-compound pharmaceuticals. Matrix effects, co-eluting compounds, and lack of reference standards complicate accuracy, precision, and specificity assessments. Harmonization of analytical methodologies across laboratories and jurisdictions remains incomplete, hindering comparability of quality data.

Standard reference material availability represents a critical gap, particularly for less common botanical species and specific phytochemical markers. The development, characterization, and certification of botanical reference materials require substantial resources and collaborative efforts. Authentication of botanical identity using traditional morphological and microscopic methods becomes increasingly challenging with processed materials and extracts.

Scalability of advanced analytical techniques to industrial quality control settings faces practical barriers. High-throughput requirements, cost constraints, and technical expertise availability limit routine implementation of sophisticated instrumentation and computational methods. Development of simplified, validated, yet sufficiently comprehensive analytical approaches represents an ongoing challenge.

Regulatory harmonization across international jurisdictions would facilitate global trade and reduce duplicative testing, yet remains elusive due to divergent regulatory philosophies and risk assessments. The absence of universal quality benchmarks for many botanical products complicates international commerce and clinical evidence generalization. Future perspectives highlight several promising directions for innovation. Portable analytical devices including handheld spectrometers and miniaturized chromatographic systems could enable field-level quality assessment and supply chain verification. Real-time process analytical technology (PAT) implementation would allow continuous quality monitoring during manufacturing, enabling immediate corrective actions. Artificial intelligence and machine learning applications show potential for pattern recognition, quality prediction, and fraud detection from complex analytical datasets.

Blockchain technology offers opportunities for transparent supply chain tracking and authentication verification. Omics approaches including metabolomics, genomics, and proteomics provide comprehensive biological characterization beyond traditional chemical analysis. Integration of multiple analytical platforms through data fusion strategies may capture product complexity more comprehensively than individual techniques.

Quality-by-design implementation throughout phytopharmaceutical development, from cultivation through formulation, represents a paradigm shift from reactive quality control to proactive quality assurance. Systems biology approaches recognizing the multi-component, multi-target nature of phytopharmaceuticals may inform more rational standardization strategies aligned with therapeutic mechanisms.

7. Conclusion

Phytopharmaceutical standardization and quality control have evolved into sophisticated scientific disciplines integrating advanced analytical technologies, computational methods, and comprehensive regulatory frameworks. The transition from simple marker quantification to multi-dimensional chemical fingerprinting reflects growing recognition of botanical product complexity and the necessity for holistic quality assessment. Contemporary analytical strategies employing chromatographic, spectroscopic, and hyphenated techniques provide unprecedented capabilities for characterizing phytochemical compositions and ensuring manufacturing consistency.

Regulatory frameworks established by international agencies provide essential guidelines for quality assurance, yet significant variations persist across jurisdictions, necessitating ongoing harmonization efforts. The translational relevance of rigorous quality control extends beyond regulatory compliance to encompass therapeutic reliability, patient safety, and evidence-based clinical integration. Current challenges including biological variability management, analytical method validation, standard reference material availability, and industrial scalability require continued innovation and collaboration. Future directions emphasize technological innovation through portable analytics, real-time monitoring, artificial intelligence integration, and omics approaches. The implementation of quality-by-design principles and systems biology perspectives promises more rational, mechanism-informed standardization strategies. Ultimately, continued advancement in phytopharmaceutical quality control will facilitate broader clinical acceptance, enable evidence-based therapeutic applications, and ensure that these complex botanical products achieve their full therapeutic potential while maintaining the highest standards of pharmaceutical quality.

8. Tables

Table 1: Analytical techniques used for phytopharmaceutical standardization

Technique	Principle	Applications	Advantages	Limitations
HPLC-UV/PDA	Liquid chromatography with UV detection	Marker quantification, fingerprinting	High resolution, versatility, quantitative	Limited structural information
UHPLC	Ultra-high pressure liquid chromatography	Rapid profiling, high-throughput analysis	Speed, resolution, sensitivity	Equipment cost, method transfer challenges
GC-MS	Gas chromatography-mass spectrometry	Volatile compounds, essential oils	Excellent resolution, identification	Limited to volatile/derivatizable compounds
LC-MS/HRMS	Liquid chromatography-high resolution mass spectrometry	Comprehensive metabolomics, unknowns	Structural elucidation, sensitivity	High cost, data complexity
NMR	Nuclear magnetic resonance spectroscopy	Structural characterization, quantification	No reference standards needed, non-destructive	Lower sensitivity, expensive
FTIR/NIR	Infrared spectroscopy	Rapid screening, authentication	Speed, non-destructive, minimal sample	Lower specificity, requires calibration
TLC	Thin-layer chromatography	Identity testing, preliminary screening	Simple, cost-effective, visual	Semi-quantitative, lower resolution
Capillary electrophoresis	Electrophoretic separation	Polar compounds, small sample volumes	High efficiency, minimal consumption	Method development complexity
DNA barcoding	Molecular genetics	Botanical authentication	Unambiguous identification	Requires technical expertise, costly

Table 2: Chemical markers and fingerprinting approaches

Approach	Marker Type	Examples	Botanical Products	Quality Assessment
Active marker standardization	Pharmacologically active compounds	Hypericin (St. John's wort), Silymarin (Milk thistle)	Single herb products	Direct therapeutic relevance
Analytical marker standardization	Chemically stable, easily quantified	Ginsenosides (Ginseng), Curcuminoids (Turmeric)	Standardized extracts	Manufacturing consistency
Multi-marker quantification	Multiple characteristic compounds	Flavonoids, alkaloids, terpenoids	Complex botanical products	Enhanced quality assurance
Chromatographic fingerprinting	Total peak pattern analysis	HPLC/GC profiles	Authentication, batch consistency	Holistic quality assessment
Spectroscopic fingerprinting	Spectral pattern recognition	NMR, FTIR, NIR spectra	Rapid screening, process monitoring	Requires chemometric analysis
Metabolomic profiling	Comprehensive metabolite characterization	LC-MS/GC-MS datasets	Research applications, comprehensive QC	Data complexity, resource intensive

Table 3: Advantages, limitations, and regulatory challenges of phytopharmaceutical quality control

Aspect	Advantages	Limitations	Regulatory Challenges
Chemical standardization	Ensures batch consistency, enables dosing standardization	Biological variability, matrix complexity	Lack of harmonized standards across jurisdictions
Advanced analytics	High sensitivity and specificity, comprehensive profiling	High cost, technical expertise requirements	Method validation for complex matrices
Regulatory frameworks	Quality assurance, patient safety, market credibility	Variation across regions, compliance burden	Insufficient international harmonization
Marker-based approaches	Quantitative control, straightforward implementation	May not capture total therapeutic activity	Lack of consensus on appropriate markers
Fingerprinting	Holistic quality assessment, adulteration detection	Requires sophisticated data analysis	Limited regulatory acceptance in some regions
Reference materials	Enable validation and traceability	Limited availability for many species	Need for expanded SRM development
GMP implementation	Consistent manufacturing quality	Resource intensive, complex for botanical materials	Adaptation of pharmaceutical GMP to botanicals
Clinical translation	Evidence-based practice, therapeutic reliability	Cost and time for clinical validation	Requirement for clinical evidence varies

9. Figures




Fig 1: Workflow of phytopharmaceutical standardization from raw material to final product




Fig 2: Integrated strategies for quality control and regulatory compliance

10. References

1. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Front Pharmacol*. 2014;4:177.
2. Pharmacopoeial Forum. Quality control methods for herbal materials. World Health Organization. 2018.
3. Heinrich M, Appendino G, Efferth T, *et al*. Best practice in research—overcoming common challenges in phytopharmacological research. *J Ethnopharmacol*. 2020;246:112230.
4. Wölflle U, Seelinger G, Schempp CM. Topical application of St. John's wort (*Hypericum perforatum*). *Planta Med*. 2014;80(2–3):109–120.
5. Booker A, Frommenwiler D, Reich E, *et al*. Adulteration and poor quality of Ginkgo biloba supplements. *J Herb Med*. 2016;6(2):79–87.
6. Kellogg JJ, Todd DA, Egan JM, *et al*. Biochemometrics for natural products research: comparison of data analysis approaches and application to identification of bioactive compounds. *J Nat Prod*. 2016;79(2):376–386.
7. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *J Nat Prod*. 2020;83(3):770–803.
8. World Health Organization. WHO global report on traditional and complementary medicine 2019. Geneva: WHO; 2019.
9. Chen S, Pang X, Song J, *et al*. A renaissance in herbal medicine identification: from morphology to DNA. *Biotechnol Adv*. 2014;32(7):1237–1244.
10. Pferschy-Wenzig EM, Bauer R. The relevance of pharmacognosy in pharmacological research on herbal medicinal products. *Epilepsy Behav*. 2015;52(Pt B):344–362.
11. Gad HA, El-Ahmady SH, Abou-Shoer MI, Al-Azizi MM. Application of chemometrics in authentication of herbal medicines: a review. *Phytochem Anal*. 2013;24(1):1–24.
12. Kumari R, Kotecha M. A review on the standardization of herbal medicines. *Int J Pharm Sci Res*. 2016;7(2):97–106.
13. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, *et al*. Discovery and resupply of pharmacologically active plant-derived natural products. *Biotechnol Adv*. 2015;33(8):1582–1614.
14. Zhong Y, Shahidi F. Methods for the assessment of antioxidant activity in foods. In: *Handbook of Antioxidants for Food Preservation*. Woodhead Publishing; 2015. p. 287–333.
15. Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. *Phytomedicine*. 2009;16(2–3):97–110.
16. Rasoanaivo P, Wright CW, Willcox ML, Gilbert B. Whole plant extracts versus single compounds for the treatment of malaria. *Malar J*. 2011;10(Suppl 1):S4.
17. European Medicines Agency. Guideline on quality of herbal medicinal products/traditional herbal medicinal products. EMA/CPMP/QWP/2819/00 Rev 2; 2011.
18. U.S. Food and Drug Administration. Botanical drug development: guidance for industry. Silver Spring (MD): FDA; 2016.
19. Bilia AR, Santomauro F, Sacco C, Bergonzi MC, Donato R. Essential oil of *Artemisia annua* L. *Evid Based Complement Alternat Med*. 2014;2014:159819.
20. Cañigueral S, Tschirch A. New approaches to establishing quality standards in herbal medicines. *Planta Med*. 2016;82(9–10):706–712.
21. Chandra S, Lata H, Khan IA, ElSohly MA. Photosynthetic response of *Cannabis sativa* L. *Physiol Mol Biol Plants*. 2008;14(4):299–306.
22. Chen Y, Zhu SB, Xie MY, *et al*. Quality control and discrimination of *Ganoderma lucidum*. *Anal Chim Acta*. 2008;623(2):146–156.
23. Street RA, Stirk WA, Van Staden J. South African traditional medicinal plant trade. *J Ethnopharmacol*. 2008;119(3):705–710.
24. World Health Organization. Quality control methods for medicinal plant materials. Geneva: WHO; 1998.
25. Bandaranayake WM. Quality control, screening, toxicity, and regulation of herbal drugs. In: *Modern Phytomedicine*. Wiley-VCH; 2006. p. 25–57.
26. Govindaraghavan S, Sucher NJ. Quality assessment of medicinal herbs using metabolomics. *J Ethnopharmacol*. 2015;175:291–302.
27. Tistaert C, Dejaegher B, Vander Heyden Y. Chromatographic techniques for herbal fingerprints. *Anal Chim Acta*. 2011;690(2):148–161.
28. Zhang ZL, Guo Y, Zhao YS, *et al*. Chemical fingerprinting of *Panax notoginseng*. *Chin Med*. 2016;11:34.
29. Lahlou M. Methods to study phytochemistry and bioactivity of essential oils. *Phytother Res*. 2004;18(6):435–448.
30. Rivera G, Bocanegra-García V, Monge A. Traditional plants as sources of functional foods. *CyTA J Food*. 2010;8(2):159–167.
31. Liang YZ, Xie P, Chan K. Quality control of herbal medicines. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2004;812(1–2):53–70.
32. Yang Y, Kinoshita K, Koyama K, *et al*. Anti-emetic principles of *Pogostemon cablin*. *Phytomedicine*. 1999;6(2):89–93.
33. Xie PS, Chen SB, Liang YZ, *et al*. Chromatographic fingerprint analysis for TCM. *J Chromatogr A*. 2006;1112(1–2):171–180.
34. Peng L, Wang Y, Zhu H, Chen Q. HPLC fingerprinting of *Artemisia selengensis*. *Food Chem*. 2011;125(3):1064–1071.
35. Kong WJ, Zhao YL, Xiao XH, *et al*. UPLC fingerprint analysis of *Coptidis rhizoma*. *Phytomedicine*. 2009;16(10):950–959.
36. Nikolic D, Gödecke T, Chen SN, *et al*. MS dereplication of black cohosh constituents. *Fitoterapia*. 2012;83(3):441–460.
37. Fan XH, Cheng YY, Ye ZL, *et al*. Multiple chromatographic fingerprinting for herbal medicines. *Anal Chim Acta*. 2006;555(2):217–224.
38. Cordell GA, Colvard MD. Natural products and traditional medicine. *J Nat Prod*. 2012;75(3):514–525.
39. Zhang A, Sun H, Wang P, *et al*. Modern analytical techniques in metabolomics. *Analyst*. 2012;137(2):293–300.
40. Williamson EM. Synergy and interactions in phytomedicines. *Phytomedicine*. 2001;8(5):401–409.
41. Fuzzati N. Analysis methods of ginsenosides. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2004;812(1–2):119–133.

42. Simmler C, Napolitano JG, McAlpine JB, *et al.* Quantitative NMR of complex natural samples. *Curr Opin Biotechnol.* 2014;25:51–59.
43. Sarker SD, Nahar L. Hyphenated techniques in natural products analysis. *Methods Mol Biol.* 2012;864:301–340.
44. Seger C, Sturm S, Stuppner H. HPLC-MS and HPLC-NMR in natural products research. *Nat Prod Rep.* 2013;30(7):970–987.
45. Friesen JB, McAlpine JB, Chen SN, Pauli GF. Countercurrent separation of natural products. *J Nat Prod.* 2015;78(8):1765–1796.
46. Nováková L, Vlčková H. Advances in modern bio-analytical methods. *Anal Chim Acta.* 2009;656(1–2):8–35.
47. Sherma J, Fried B. Handbook of thin-layer chromatography. 3rd ed. Boca Raton: CRC Press; 2003.
48. Marriott PJ, Shellie R, Cornwell C. Gas chromatographic technologies for essential oils. *J Chromatogr A.* 2001;936(1–2):1–22.
49. Wolfender JL, Marti G, Thomas A, Bertrand S. Metabolite profiling of complex natural extracts. *J Chromatogr A.* 2015;1382:136–164.
50. Raut JS, Shinde RB, Chauhan NM, Karuppayil SM. Phenylpropanoids as inhibitors of *Candida albicans* biofilms. *J Microbiol Biotechnol.* 2014;24(9):1216–1225.
51. García-Pérez E, Castro-Puyana M, Marina ML, Plaza M. Analytical methods for *Cistus* species. *J Chromatogr A.* 2015;1407:75–93.
52. Zhang A, Sun H, Wang X. Natural products for liver diseases. *Eur J Med Chem.* 2013;63:570–577.
53. Marston A. TLC with biological detection in phytochemistry. *J Chromatogr A.* 2011;1218(19):2676–2683.
54. Wang X, Zhang A, Sun H, *et al.* Chinmedomics strategies in drug discovery. *TrAC Trends Anal Chem.* 2016;76:86–94.
55. Zhang A, Sun H, Wang X. Power of metabolomics in obesity biomarker discovery. *Obes Rev.* 2013;14(4):344–349.
56. Wolfender JL, Ndjoko K, Hostettmann K. LC-UV-MS and LC-NMR for plant metabolites. *J Chromatogr A.* 2003;1000(1–2):437–455.
57. Schulz H, Baranska M. Identification of plant substances by IR and Raman spectroscopy. *Vib Spectrosc.* 2007;43(1):13–25.
58. Pauli GF, Chen SN, Simmler C, *et al.* Importance of purity evaluation using quantitative NMR. *J Med Chem.* 2014;57(22):9220–9231.